Human Brain and CognitionNCT06236399
An EEG Study on the Rhythmic Nature of Perception and Attention
An observational study of Human Brain and Cognition, run by Università Vita-Salute San Raffaele at 1 site in Italy.
Trial summary
The study involved healthy volunteers (n= 200), in a single center, low-risk intervention protocol of a non-profit nature. The objective of the study is to investigate the neural mechanisms of visual perception and attention, with particular reference to neural oscillations, in the general population through… Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Human Brain and Cognition
- How many people
- 200 participants
- Where
- 1 siteItaly
- Study dates
- 13 Nov 2023to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Healthy human volunteers
Who may be able to join
- age between 18 and 35 years
- able/willing to sign the informed consent
- normal or corrected-to-normal vision and hearing
Who cannot join
- history of severe/major neurological or psychiatric conditions
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
IRCCS Ospedale San Raffaele
Milan, 20132
Luca Ronconi, 0226434887, ronconi.luca@unisr.it
About this study
Official title: EEG Study of the Rhythmic Nature of Human Visual Perception and Attention
The study involved healthy volunteers (n= 200), in a single center, low-risk intervention protocol of a non-profit nature. The objective of the study is to investigate the neural mechanisms of visual perception and attention, with particular reference to neural oscillations, in the general population through electroencephalogram (EEG) recording and the administration of simple visual tasks on a PC. The study presented is not associated with risks, as EEG is a non-invasive technique for which there are no known contraindications or adverse reactions.
- Conditions
- Human Brain and Cognition
What is being measured
The primary outcome is the main question the study is designed to answer.
Electroencephalographic (EEG) oscillatory amplitude
Amplitude of EEG oscillations in theta, alpha and beta frequency bands
Measured: during the intervention
Electroencephalographic (EEG) oscillatory frequency
Frequency of EEG oscillations in theta, alpha and beta frequency bands
Measured: during the intervention
Electroencephalographic (EEG) oscillatory phase coherence
Phase coherence of EEG oscillations in theta, alpha and beta frequency bands
Measured: during the intervention
Autism Quotient (AQ)
Personality questionnaire measuring subclinical autistic traits. Higher score mean worse outcome. Score range: min.= 0, max.= 50.
Measured: during the intervention
Schizotypal Personality Questionnaire (SPQ)
Personality questionnaire measuring subclinical schizotypal traits. Higher score mean worse outcome. Score range: min.= 0, max.= 74.
Measured: during the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Feb 2024
- Study start13 Nov 2023
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Brain and CognitionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Università Vita-Salute San Raffaele
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Luca Ronconi, Università Vita-Salute San Raffaele
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06236399
- Sponsor's protocol ID
- EEGVISION-01
- Status last verified
- Apr 2024
- First submitted
- 8 Jan 2024
- Last updated
- 10 Apr 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EEG Study of the Rhythmic Nature of Human Visual Perception and Attention
- ClinicalTrials.gov ID
- NCT06236399
- Acronym / sponsor ID
- EEGVISION-01
- Conditions
- Human Brain and Cognition
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Università Vita-Salute San RaffaeleUniversity, hospital or other
- Study start
- 13 Nov 2023 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 1 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study involved healthy volunteers (n= 200), in a single center, low-risk intervention protocol of a non-profit nature. The objective of the study is to investigate the neural mechanisms of visual perception and attention, with particular reference to neural oscillations, in the general population through electroencephalogram (EEG) recording and the administration of simple visual tasks on a PC. The study presented is not associated with risks, as EEG is a non-invasive technique for which there are no known contraindications or adverse reactions.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Healthy human volunteers
Key inclusion criteria (3 listed)
- age between 18 and 35 years
- able/willing to sign the informed consent
- normal or corrected-to-normal vision and hearing
Key exclusion criteria (1 listed)
- history of severe/major neurological or psychiatric conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Electroencephalographic (EEG) oscillatory amplitude
Time frame: during the intervention
Amplitude of EEG oscillations in theta, alpha and beta frequency bands
Electroencephalographic (EEG) oscillatory frequency
Time frame: during the intervention
Frequency of EEG oscillations in theta, alpha and beta frequency bands
Electroencephalographic (EEG) oscillatory phase coherence
Time frame: during the intervention
Phase coherence of EEG oscillations in theta, alpha and beta frequency bands
Autism Quotient (AQ)
Time frame: during the intervention
Personality questionnaire measuring subclinical autistic traits. Higher score mean worse outcome. Score range: min.= 0, max.= 50.
Schizotypal Personality Questionnaire (SPQ)
Time frame: during the intervention
Personality questionnaire measuring subclinical schizotypal traits. Higher score mean worse outcome. Score range: min.= 0, max.= 74.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2024.
Related trials for Human Brain and Cognition
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingPhase 2/3
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Huntington Disease
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults
Healthy Aging
Not yet recruiting
Prediction and Prevention of Postoperative Mortality and Morbidity
Dementia, Postoperative Delirium (POD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Brain and Cognition, run by Università Vita-Salute San Raffaele at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Luca Ronconi, PhD (0226434887 ext. +39, ronconi.luca@unisr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Electroencephalographic (EEG) oscillatory amplitude (time frame: during the intervention). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2024.